Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

OBJECTIVES: MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA). METHODS: This phase 3b, double-blind, placebo-controlled, multi-centre 52-we...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraliakos, Xenofon, Gossec, Laure, Pournara, Effie, Jeka, Slawomir, Mera-Varela, Antonio, D'Angelo, Salvatore, Schulz, Barbara, Rissler, Michael, Nagar, Kriti, Perella, Chiara, Coates, Laura C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053347/
https://www.ncbi.nlm.nih.gov/pubmed/33334727
http://dx.doi.org/10.1136/annrheumdis-2020-218808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053347/
https://www.ncbi.nlm.nih.gov/pubmed/33334727
http://dx.doi.org/10.1136/annrheumdis-2020-218808

Ejemplares similares